The impact of comorbid allergic airway disease on the severity and mortality of COVID-19: a systematic review and meta-analysis

Wei, Ming; Zuo, Jingjing; Han, Jibo; Chen, Jinhui

doi:10.1007/s00405-021-07072-1

Cited by 5 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, we found 40, 96, and 35 eligible SLRs published in 2020, 2021, and 2022 (until April), respectively. Due to the high volume of retrieved evidence and the anticipated overlap across SLRs with regard to the studies included, we decided to focus on the most recent evidence from the 35 SLRs published in early 2022, 6,17–45 as we expect that SLRs published in 2022 include most of the evidence considered in previous SLRs when assessing the same predictor(s). In addition, we extracted key descriptive information for the included SLRs (fitting our protocol inclusion criteria) published in 2021 (reference citation and type of risk factors/predictors in each SLRs).…”

Section: Resultsmentioning

confidence: 99%

“…The quality of primary studies was assessed in 86% (30 of 35) of the included SLRs, 11 of which used the Newcastle-Ottawa scale, 24,27,34,41,42,[44][45][46]48,51 5 SLRs used the Quality in Prognostic Studies tool, 18,20,21,31,39 and 2 SLRs used Strengthening the Reporting of Observational studies in Epidemiology, 37,47 Risk of Bias in Non-randomized Studies -of Interventions, 43,52 and Grading of Recommendations Assessment, Development and Evaluation, 36,38 respectively.…”

Section: Characteristics Of Slrs Published Between January 2022 and A...mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology

Sarri¹,

Liu

Zabotka

et al. 2023

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

During the coronavirus disease 2019 (COVID‐19) pandemic, the urgency for updated evidence to inform public health and clinical care placed systematic literature reviews (SLRs) at the cornerstone of research. We aimed to summarize evidence on prognostic factors for COVID‐19 outcomes through published SLRs and to critically assess quality elements in the findings' interpretation. An umbrella review was conducted via electronic databases from January 2020 to April 2022. All SLRs (and meta‐analyses) in English were considered. Data screening and extraction were conducted by two independent reviewers. AMSTAR 2 tool was used to assess SLR quality. The study was registered with PROSPERO (CRD4202232576). Out of 4,564 publications, 171 SLRs were included of which 3 were umbrella reviews. Our primary analysis included 35 SLRs published in 2022, which incorporated studies since the beginning of the pandemic. Consistent findings showed that, for adults, older age, obesity, heart disease, diabetes, and cancer were more strongly predictive of risk of hospitalization, intensive care unit admission, and mortality due to COVID‐19. Male sex was associated with higher risk of short‐term adverse outcomes, but female sex was associated with higher risk of long COVID. For children, socioeconomic determinants that may unravel COVID‐19 disparities were rarely reported. This review highlights key prognostic factors of COVID‐19, which can help clinicians and health officers identify high‐risk groups for optimal care. Findings can also help optimize confounding adjustment and patient phenotyping in comparative effectiveness research. A living SLR approach may facilitate dissemination of new findings. This paper is endorsed by the International Society for Pharmacoepidemiology.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Characteristics Of Slrs Published Between January 2022 and A...mentioning

confidence: 99%

Prognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology

Sarri¹,

Liu

Zabotka

et al. 2023

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…The nature of asthma either allergic or nonallergic is also found to be involved in minimizing the risks, and the allergic nature seemed to be in favor of minimal risk [ 40 ]. The Th phenotype of asthma may have significantly different COVID-19 prognosis as shown by Bloom et al [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of Preexisting Asthma on the Risk of ICU Admission, Intubation, and Death from COVID-19: A Systematic Review and Meta-Analysis

Bhattarai

Dhakal

Shah

et al. 2022

Interdisciplinary Perspectives on Infectious Diseases

View full text Add to dashboard Cite

Background. The Centers for Disease Control and Prevention (CDC) identifies asthma as a comorbidity in COVID-19 that increases the risk of severity and death. However, research has shown that asthma is not associated with increased severity and death, thus making the consequences of asthma in COVID-19 unclear. Methods. We searched the electronic databases PubMed, WHO COVID-19 database, and Taylor and Francis Online for studies that compared the medical outcomes of COVID-19 between patients with and without asthma, from the emergence of SARS-CoV-2 in December 2019 to the 3rd of September 2021, excluded duplicates, reviews, editorials, and case reports, and screened the titles, abstracts, and full texts. The quality of the included studies was assessed using the Newcastle–Ottawa Scale (NOS) for nonrandomized studies. Rates of intensive care unit (ICU) admission, intubation, and death among patients with and without asthma were compiled and meta-analysis was conducted using a random-effects model. Results. Nineteen studies with a total of 289,449 participants met the inclusion criteria. COVID-19 patients with asthma had no significant association with increased risk of ICU admission, intubation, and death as compared with those without asthma ((odds ratio (OR) = 1.25, confidence interval (CI) = 0.90–1.74, I2 = 82%, X2 = 55.13, p < 0.01 ), (OR = 0.89, CI = 0.59–1.34, I2 = 91%, X2 = 110.82, p < 0.01 ), and (OR = 0.90, 95% CI = 0.63–1.27, I2 = 88%, X2 = 146.96, p < 0.01 )), respectively. Conclusion. Preexisting asthma did not significantly increase the risk of poorer prognosis and death from COVID-19.

show abstract

“…Another evident issue became the similarities in presentation between AR and COVID‐19, and it was important to identify ways to differentiate the diseases 3363,3364 . AR was not a risk factor for severe COVID‐19 infection 3370–3377 . The consensus from a survey distributed to members of the ARIA/EAACI study group was that AR presented with runny nose, sneezing, stuffy nose, nasal pruritus, ocular pruritis, and redness compared to COVID‐19 which presented with more smell and taste dysfunction, dyspnea, and cough 3378 .…”

Section: Special Section On Covid‐19mentioning

confidence: 99%

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

113

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

The impact of comorbid allergic airway disease on the severity and mortality of COVID-19: a systematic review and meta-analysis

Cited by 5 publications

References 51 publications

Prognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology

Prognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology

Effect of Preexisting Asthma on the Risk of ICU Admission, Intubation, and Death from COVID-19: A Systematic Review and Meta-Analysis

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Contact Info

Product

Resources

About